Bio Green Med Solution Inc (BGMS)

$1.21 -0.02 (-1.63%)
Market Cap 5.93M
Revenue (ttm) 40,000.00
Net Income (ttm) -11.21M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -28,025.00%
Debt to Equity Ratio 0.00
Volume 21,700
Avg Vol 45,278
Day's Range N/A - N/A
Shares Out 4.90M
Stochastic %K 7%
Beta -0.45
Analysts Hold
Price Target N/A

Company Profile

Bio Green Med Solution, Inc. engages in the distributing, trading, and installation of protective and fire safety materials and equipment, and fire protection and prevention systems. It also researches and develops pharmaceuticals. The company was formerly known as Cyclacel Pharmaceuticals, Inc. and changed its name to Bio Green Med Solution, Inc. in September 2022. The company was founded in 1996 and is headquartered in Kuala Lumpur, Malaysia.

Industry: Biotechnology
Sector: Healthcare
Phone: 60 9 08517 7330
Address:
Level 10, Tower 11 Avenue 5, No. 8 Jalan Kerinchi, Kuala Lumpur, Malaysia
Clinton777
Clinton777 Jan. 29 at 7:23 AM
$BGMS
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 20 at 11:28 PM
$BGMS RSI: 50.77, MACD: -0.0372 Vol: 0.08, MA20: 1.43, MA50: 1.44 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
djcal
djcal Jan. 18 at 8:40 PM
$BGMS Had shares when it was CYCC for years. They never did anything in those years. Pure scam. Now they acquire this fire equipment stock and tie it with there existing biopharm scam so now it is a double scam. You will lose money.
0 · Reply
bahjatbern
bahjatbern Jan. 14 at 7:30 PM
$BGMS i am here only to remind my self about trading scam stocks , always trust your inner feelings
0 · Reply
mightyshrimp
mightyshrimp Jan. 14 at 2:50 PM
$BGMS with all the gains over the last few days, I’m now only down 99.95%! 💩
1 · Reply
topstockalerts
topstockalerts Jan. 12 at 9:31 PM
After Hours Top Gainers PT2 $DRCT $BGMS $FBLG $LVLU $QTRX
0 · Reply
BillionerOfKing
BillionerOfKing Jan. 2 at 1:02 AM
$BGMS Current Stock Price: $1.50
0 · Reply
UmbraUpholstery
UmbraUpholstery Dec. 26 at 5:29 PM
$BGMS Market structure is quietly punishing unfocused strategies. Governance alignment should reduce uncertainty over time. Missteps would reset expectations abruptly. Execution quality will determine whether momentum is sustainable.
1 · Reply
GoldRushGuy
GoldRushGuy Dec. 24 at 12:02 PM
$BGMS Future price discovery depends on how progress validates the underlying thesis beyond narrative appeal. The window for proof-of-execution is narrowing.
0 · Reply
SPYmyQQQ
SPYmyQQQ Dec. 22 at 10:26 PM
🎯 Target Hit 🏁 📨 From Dec 16, 2025 💊 $BGMS 💵 Entry: $1.3500 ✅ Ext: $1.5601 💰 P/L: +15.56% 👉 FREE TRIAL! spymyqqq/join/
0 · Reply
Latest News on BGMS
Bio Green Med Solution Reports Third Quarter Financial Results and Provides Business Update

Nov 13, 2025, 4:40 PM EST - 2 months ago

Bio Green Med Solution Reports Third Quarter Financial Results and Provides Business Update

Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update

Aug 13, 2025, 4:05 PM EDT - 6 months ago

Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update

CYCLACEL PHARMACEUTICALS HIGHLIGHTS PRECLINICAL DATA SHOWING THAT CANCER OF THE BILIARY TRACT IS SENSITIVE TO PLOGOSERTIB

Aug 4, 2025, 6:50 PM EDT - 6 months ago

CYCLACEL PHARMACEUTICALS HIGHLIGHTS PRECLINICAL DATA SHOWING THAT CANCER OF THE BILIARY TRACT IS SENSITIVE TO PLOGOSERTIB

Why Is Cyclacel Pharmaceuticals Stock Soaring On Tuesday?

Jul 15, 2025, 12:17 PM EDT - 7 months ago

Why Is Cyclacel Pharmaceuticals Stock Soaring On Tuesday?

CYCLACEL PHARMACEUTICALS HIGHLIGHTS PUBLICATION OF PRECLINICAL DATA SHOWING THAT PLOGOSERTIB IS ACTIVE IN A HARD-TO-TREAT SUBTYPE OF LIVER CANCER

Jul 7, 2025, 6:00 AM EDT - 7 months ago

CYCLACEL PHARMACEUTICALS HIGHLIGHTS PUBLICATION OF PRECLINICAL DATA SHOWING THAT PLOGOSERTIB IS ACTIVE IN A HARD-TO-TREAT SUBTYPE OF LIVER CANCER

CYCLACEL PHARMACEUTICALS ANNOUNCES AMENDMENT TO EXCHANGE AGREEMENT

Jul 7, 2025, 6:00 AM EDT - 7 months ago

CYCLACEL PHARMACEUTICALS ANNOUNCES AMENDMENT TO EXCHANGE AGREEMENT

Cyclacel Pharmaceuticals Announces Stock Split

Jul 2, 2025, 9:00 AM EDT - 7 months ago

Cyclacel Pharmaceuticals Announces Stock Split

Cyclacel Pharmaceuticals Announces $3 Million Private Placement Offering of Convertible Preferred Stock

Jun 20, 2025, 4:30 PM EDT - 8 months ago

Cyclacel Pharmaceuticals Announces $3 Million Private Placement Offering of Convertible Preferred Stock

CYCLACEL PHARMACEUTICALS REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT

Jun 3, 2025, 4:15 PM EDT - 8 months ago

CYCLACEL PHARMACEUTICALS REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT

CYCLACEL PHARMACEUTICALS REPORTS FIRST QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

May 15, 2025, 12:50 AM EDT - 9 months ago

CYCLACEL PHARMACEUTICALS REPORTS FIRST QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

CYCLACEL PHARMACEUTICALS ANNOUNCES STOCK SPLIT

May 7, 2025, 9:00 AM EDT - 9 months ago

CYCLACEL PHARMACEUTICALS ANNOUNCES STOCK SPLIT

CYCLACEL PHARMACEUTICALS, INC. ANNOUNCES EXECUTION OF SHARE EXCHANGE AGREEMENT TO MAKE FITTERS SDN.

May 6, 2025, 6:00 AM EDT - 9 months ago

CYCLACEL PHARMACEUTICALS, INC. ANNOUNCES EXECUTION OF SHARE EXCHANGE AGREEMENT TO MAKE FITTERS SDN.

Cyclacel Pharmaceuticals Reports Fourth Quarter Financial Results and Provides Business Update

Apr 2, 2025, 4:05 PM EDT - 10 months ago

Cyclacel Pharmaceuticals Reports Fourth Quarter Financial Results and Provides Business Update

Cyclacel Pharmaceuticals Announces $1 Million Private Placement Offering of Convertible Preferred Stock

Mar 24, 2025, 7:30 AM EDT - 11 months ago

Cyclacel Pharmaceuticals Announces $1 Million Private Placement Offering of Convertible Preferred Stock

Cyclacel Pharmaceuticals Announces Closing of a Change of Control Transaction and Appointment of New Executive Leadership

Feb 27, 2025, 1:38 PM EST - 1 year ago

Cyclacel Pharmaceuticals Announces Closing of a Change of Control Transaction and Appointment of New Executive Leadership

Cyclacel Pharmaceuticals Announces Agreement for the Acquisition of Preferred Stock by David Lazar

Jan 3, 2025, 9:01 AM EST - 1 year ago

Cyclacel Pharmaceuticals Announces Agreement for the Acquisition of Preferred Stock by David Lazar

Cyclacel Pharmaceuticals Announces Its Exploration of Potential Strategic Alternatives and Reduction of Operating Costs

Dec 5, 2024, 4:05 PM EST - 1 year ago

Cyclacel Pharmaceuticals Announces Its Exploration of Potential Strategic Alternatives and Reduction of Operating Costs

Cyclacel Pharmaceuticals Announces Closing of Exercise of Warrants for $2.1 Million Gross Proceeds

Nov 14, 2024, 4:15 PM EST - 1 year ago

Cyclacel Pharmaceuticals Announces Closing of Exercise of Warrants for $2.1 Million Gross Proceeds

Cyclacel Pharmaceuticals Announces Exercise of Warrants for $2.1 Million Gross Proceeds

Nov 13, 2024, 12:22 PM EST - 1 year ago

Cyclacel Pharmaceuticals Announces Exercise of Warrants for $2.1 Million Gross Proceeds

Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update

Nov 12, 2024, 4:45 PM EST - 1 year ago

Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update

Cyclacel Pharmaceuticals Announces That Nasdaq Granted an Extension to Regain Compliance With the Equity Standard Rule

Oct 24, 2024, 9:15 AM EDT - 1 year ago

Cyclacel Pharmaceuticals Announces That Nasdaq Granted an Extension to Regain Compliance With the Equity Standard Rule

Cyclacel Pharmaceuticals Reports New Clinical Data from Ongoing, Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium

Oct 23, 2024, 9:15 AM EDT - 1 year ago

Cyclacel Pharmaceuticals Reports New Clinical Data from Ongoing, Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium

Cyclacel Pharmaceuticals to Present New Clinical Data From Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium

Oct 9, 2024, 9:15 AM EDT - 1 year ago

Cyclacel Pharmaceuticals to Present New Clinical Data From Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium

Cyclacel Pharmaceuticals Announces Completion of Enrollment in the Biomarker-Enriched Patient Cohort of Its Phase 2 Study

Sep 25, 2024, 9:15 AM EDT - 1 year ago

Cyclacel Pharmaceuticals Announces Completion of Enrollment in the Biomarker-Enriched Patient Cohort of Its Phase 2 Study

Cyclacel Pharmaceuticals Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 4, 2024, 9:15 AM EDT - 1 year ago

Cyclacel Pharmaceuticals Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference

Cyclacel Pharmaceuticals Confirms It Has Filed an Appeal to Nasdaq Staff Delisting Letter

Sep 3, 2024, 9:15 AM EDT - 1 year ago

Cyclacel Pharmaceuticals Confirms It Has Filed an Appeal to Nasdaq Staff Delisting Letter

Cyclacel Pharmaceuticals, Inc. (CYCC) Q2 2024 Earnings Call Transcript

Aug 14, 2024, 8:18 PM EDT - 1 year ago

Cyclacel Pharmaceuticals, Inc. (CYCC) Q2 2024 Earnings Call Transcript

Cyclacel Pharmaceuticals to Release Second Quarter 2024 Financial Results

Aug 7, 2024, 9:15 AM EDT - 1 year ago

Cyclacel Pharmaceuticals to Release Second Quarter 2024 Financial Results

Cyclacel Announces Notice of Intention to Grant New European Patent Covering Plogosertib Pharmaceutical Compositions

Jun 26, 2024, 9:15 AM EDT - 1 year ago

Cyclacel Announces Notice of Intention to Grant New European Patent Covering Plogosertib Pharmaceutical Compositions

Cyclacel's Fadraciclib Demonstrates Efficacy in Patient-Derived Colorectal Cancer Models at the 2024 ASCO Annual Meeting

Jun 4, 2024, 8:00 AM EDT - 1 year ago

Cyclacel's Fadraciclib Demonstrates Efficacy in Patient-Derived Colorectal Cancer Models at the 2024 ASCO Annual Meeting

Cyclacel Pharmaceuticals, Inc. (CYCC) Q1 2024 Earnings Call Transcript

May 14, 2024, 8:08 PM EDT - 1 year ago

Cyclacel Pharmaceuticals, Inc. (CYCC) Q1 2024 Earnings Call Transcript

Cyclacel Pharmaceuticals to Release First Quarter 2024 Financial Results

May 8, 2024, 9:15 AM EDT - 1 year ago

Cyclacel Pharmaceuticals to Release First Quarter 2024 Financial Results

Cyclacel Pharmaceuticals Announces Closing of $8.0 Million Private Placement Priced At-The-Market Under NASDAQ Rules

May 2, 2024, 4:30 PM EDT - 1 year ago

Cyclacel Pharmaceuticals Announces Closing of $8.0 Million Private Placement Priced At-The-Market Under NASDAQ Rules

Cyclacel Pharmaceuticals Announces $8.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Apr 30, 2024, 7:00 AM EDT - 1 year ago

Cyclacel Pharmaceuticals Announces $8.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib's Potential as a Precision Medicine for Cancer

Apr 1, 2024, 9:15 AM EDT - 1 year ago

Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib's Potential as a Precision Medicine for Cancer

Cyclacel Pharmaceuticals, Inc. (CYCC) Q4 2023 Earnings Call Transcript

Mar 19, 2024, 6:09 PM EDT - 2 years ago

Cyclacel Pharmaceuticals, Inc. (CYCC) Q4 2023 Earnings Call Transcript

Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Mar 19, 2024, 4:05 PM EDT - 2 years ago

Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial Results

Mar 13, 2024, 4:05 PM EDT - 2 years ago

Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial Results

Cyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024

Mar 7, 2024, 9:15 AM EST - 2 years ago

Cyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024

Cyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax Credit

Mar 6, 2024, 9:15 AM EST - 2 years ago

Cyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax Credit

Cyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor Conference

Feb 20, 2024, 9:15 AM EST - 2 years ago

Cyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor Conference

Cyclacel Pharmaceuticals Announces the Appointment of Brian Schwartz, M.D. as Chief Medical Officer

Jan 30, 2024, 9:15 AM EST - 2 years ago

Cyclacel Pharmaceuticals Announces the Appointment of Brian Schwartz, M.D. as Chief Medical Officer

Cyclacel Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Requirement

Jan 8, 2024, 9:15 AM EST - 2 years ago

Cyclacel Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Requirement

Cyclacel Pharmaceuticals to Present at Biotech Showcase 2024

Jan 2, 2024, 9:15 AM EST - 2 years ago

Cyclacel Pharmaceuticals to Present at Biotech Showcase 2024

Cyclacel Pharmaceuticals Announces Registered Direct and Private Placement Offering Priced At-The-Market Under Nasdaq Rules

Dec 22, 2023, 9:15 AM EST - 2 years ago

Cyclacel Pharmaceuticals Announces Registered Direct and Private Placement Offering Priced At-The-Market Under Nasdaq Rules

Cyclacel Pharmaceuticals Reports Fadraciclib Phase 1 Data Suggesting Efficacy Against Tumors With CDKN2A, CDKN2B and MTAP Deletions

Dec 18, 2023, 9:00 AM EST - 2 years ago

Cyclacel Pharmaceuticals Reports Fadraciclib Phase 1 Data Suggesting Efficacy Against Tumors With CDKN2A, CDKN2B and MTAP Deletions

Cyclacel Pharmaceuticals Announces Reverse Stock Split

Dec 12, 2023, 4:05 PM EST - 2 years ago

Cyclacel Pharmaceuticals Announces Reverse Stock Split

Cyclacel Regains Compliance With Nasdaq Listing Rule Following Filing of Its Form 10-Q With the SEC

Nov 30, 2023, 9:15 AM EST - 2 years ago

Cyclacel Regains Compliance With Nasdaq Listing Rule Following Filing of Its Form 10-Q With the SEC

Cyclacel Receives Notification of Deficiency From Nasdaq Regarding Timely Filing of Quarterly Report on Form 10-Q

Nov 28, 2023, 5:15 PM EST - 2 years ago

Cyclacel Receives Notification of Deficiency From Nasdaq Regarding Timely Filing of Quarterly Report on Form 10-Q

Cyclacel Pharmaceuticals, Inc. (CYCC) Q3 2023 Earnings Call Transcript

Nov 13, 2023, 7:32 PM EST - 2 years ago

Cyclacel Pharmaceuticals, Inc. (CYCC) Q3 2023 Earnings Call Transcript

Clinton777
Clinton777 Jan. 29 at 7:23 AM
$BGMS
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 20 at 11:28 PM
$BGMS RSI: 50.77, MACD: -0.0372 Vol: 0.08, MA20: 1.43, MA50: 1.44 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
djcal
djcal Jan. 18 at 8:40 PM
$BGMS Had shares when it was CYCC for years. They never did anything in those years. Pure scam. Now they acquire this fire equipment stock and tie it with there existing biopharm scam so now it is a double scam. You will lose money.
0 · Reply
bahjatbern
bahjatbern Jan. 14 at 7:30 PM
$BGMS i am here only to remind my self about trading scam stocks , always trust your inner feelings
0 · Reply
mightyshrimp
mightyshrimp Jan. 14 at 2:50 PM
$BGMS with all the gains over the last few days, I’m now only down 99.95%! 💩
1 · Reply
topstockalerts
topstockalerts Jan. 12 at 9:31 PM
After Hours Top Gainers PT2 $DRCT $BGMS $FBLG $LVLU $QTRX
0 · Reply
BillionerOfKing
BillionerOfKing Jan. 2 at 1:02 AM
$BGMS Current Stock Price: $1.50
0 · Reply
UmbraUpholstery
UmbraUpholstery Dec. 26 at 5:29 PM
$BGMS Market structure is quietly punishing unfocused strategies. Governance alignment should reduce uncertainty over time. Missteps would reset expectations abruptly. Execution quality will determine whether momentum is sustainable.
1 · Reply
GoldRushGuy
GoldRushGuy Dec. 24 at 12:02 PM
$BGMS Future price discovery depends on how progress validates the underlying thesis beyond narrative appeal. The window for proof-of-execution is narrowing.
0 · Reply
SPYmyQQQ
SPYmyQQQ Dec. 22 at 10:26 PM
🎯 Target Hit 🏁 📨 From Dec 16, 2025 💊 $BGMS 💵 Entry: $1.3500 ✅ Ext: $1.5601 💰 P/L: +15.56% 👉 FREE TRIAL! spymyqqq/join/
0 · Reply
SPYmyQQQ
SPYmyQQQ Dec. 22 at 10:25 PM
🎯 Target Hit 🏁 📨 From Dec 19, 2025 💊 $BGMS 💵 Entry: $1.3500 ✅ Ext: $1.6100 💰 P/L: +19.26% 👉 FREE TRIAL! spymyqqq/join/
0 · Reply
ChartChartist
ChartChartist Dec. 5 at 10:53 PM
$BGMS i know beautiful $MRNO they’ll pick you up real soon, and with massive volume
0 · Reply
kshonstocks
kshonstocks Dec. 5 at 11:48 AM
keep eye on $BGMS off the bottom
0 · Reply
DaBullRunner
DaBullRunner Dec. 1 at 3:45 PM
$SMX watching carefully 🚨TOVX🚨 I’m POUNDING the table here 🚨 They have a multitude of BIG catalysts coming soon This doesn’t belong this low I’m even willing to put some of my TSLA COIN profits into TOVX👇💰💰💰 $KTTA $YXT $BGMS $FLYE let’s get it
0 · Reply
SPYmyQQQ
SPYmyQQQ Nov. 25 at 1:16 PM
🎯 Target Hit 🏁 📨 From Nov 18, 2025 💊 $BGMS 💵 Entry: $1.2700 ✅ Ext: $1.4700 💰 P/L: +15.75% 👉 FREE TRIAL! spymyqqq/join/
0 · Reply
Bittiesandteer
Bittiesandteer Nov. 18 at 8:40 PM
$BGMS low float and room to move up
0 · Reply
IWillGetThisRight
IWillGetThisRight Nov. 18 at 6:19 PM
$BGMS Interesting volume spike here.
0 · Reply
dln101
dln101 Nov. 18 at 5:42 PM
$TNON need some news $GLMD style to start bouncing back to $BGMS levels 🤔💪🔥🚀
0 · Reply
d_risk
d_risk Nov. 13 at 10:05 PM
$BGMS - Bio Green Med Solution, Inc. - 10Q - Updated Risk Factors BGMS warns of shareholder dilution and potential stock price pressure from its FITTERS deal, risks of significant minority influence by FITTERS, integration challenges, exposure to unknown liabilities, and possible earnings volatility or goodwill impairment from acquisition accounting. #Healthcare #EarningsVolatility #MinorityInfluence #ShareholderDilution #AcquisitionRisk 🟢 Added 🟠 Removed https://d-risk.ai/BGMS/10-Q/2025-11-13
0 · Reply
ward007
ward007 Nov. 10 at 2:49 PM
$BGMS is anyone here considering this is a reverse merger and once Fitters’ revenue is consolidated, BGMS could look very different from the “biotech shell” most assume it still is?
3 · Reply
bahjatbern
bahjatbern Nov. 3 at 6:57 PM
$BGMS 9% profit within one day not bad at all
0 · Reply
TheQueen2014
TheQueen2014 Nov. 3 at 2:46 PM
$BGMS waiting for pump
0 · Reply